The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). This state-of-art review provides a historical perspective of the development of the mRSS, summarizes the performance of mRSS as an outcome measure, provides guidance on assessing mRSS, and makes recommendations for incorporation of the mRSS into clinical trials.
LeRoyECMedsgerTAJrCriteria for the classification of early systemic sclerosis.J Rheumatol2001;28 (7):1573–1576Published online July 27, 2001.
2.
PereraAFertigNLucasMet al.Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.Arthritis Rheumatol2007;56 (8):2740–2746
3.
ShandLLuntMNihtyanovaSet al.Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.Arthritis Rheumatol2007;56 (7):2422–2431
4.
ClementsPJWongWKHurwitzELet al.The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.Arthritis Rheum2001;44 (3):653–661
5.
ClementsPJHurwitzELWongWKet al.Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.Arthritis Rheum2000;43 (11):2445–2454
6.
DomsicRTRodriguez-ReynaTLucasMFertigNMedsgerTAJrSkin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.Ann Rheum Dis2011;70 (1):104–109
7.
SteenVDMedsgerTAJrImprovement in skin thickening in systemic sclerosis associated with improved survival.Arthritis Rheum2001;44 (12):2828–2835
8.
DobrotaRMaurerBGrafNet al;EUSTAR coauthors.Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis2016;75 (10):1743–1748
9.
MaurerBGrafNMichelBAet al;EUSTAR co-authors.Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis2015;74 (6):1124–1131
10.
RodnanGPLipinskiELuksickJSkin thickness and collagen content in progressive systemic sclerosis and localized scleroderma.Arthritis Rheum1979;22 (2):130–140
11.
SteenVDMedsgerTAJrRodnan GP.D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med1982;97 (5):652–659
12.
ClementsPJLachenbruchPASeiboldJRet al.Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.J Rheumatol1993;20 (11):1892–1896
13.
ClementsPJFurstDEWongWKet al.High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.Arthritis Rheum1999;42 (6):1194–1203
ClementsPJLachenbruchPANgSCSimmonsMSterzMFurstDESkin score.A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum1990;33 (8):1256–1263
16.
MendozaFANagleSJLeeJBJimenezSAA prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.J Rheumatol2012;39 (6):1241–1247
17.
ClementsPJMeasuring disease activity and severity in scleroderma.Curr Opin Rheumatol1995;7 (6):517–521
18.
MerkelPAAydinSZBoersMet al.The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.J Rheumatol2011;38 (7):1480–1486
19.
MerkelPASillimanNPDentonCPet al;CAT-192 Research Group; Scleroderma Clinical Trials Consortium.Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum2008;59 (5):699–705
20.
WieseABBerrocalVJFurstDEet al.Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.Arthritis Care Res (Hoboken)2014;66 (11):1731–1739
21.
KaloudiOBandinelliFFilippucciEet al.High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis.Ann Rheum Dis2010;69 (6):1140–1143
22.
FurstDEClementsPJSteenVDet al.The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.J Rheumatol1998;25 (1):84–88
23.
KissinEYMerkelPALafyatisRMyofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.Arthritis Rheum2006;54 (11):3655–3660
24.
TashkinDPElashoffRClementsPJet al;Scleroderma Lung Study Research Group.Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med2006;354 (25):2655–2666
25.
van LaarJMFargeDSontJKet al;EBMT/EULAR Scleroderma Study Group.Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA2014;311 (24):2490–2498
26.
KhannaDDentonCPJahreisAet al.Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.Lancet2016;387 (10038):2630–2640
27.
KhannaDFurstDEHaysRDet al.Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.Ann Rheum Dis2006;65 (10):1325–1329
28.
ScottDLChoyEHGreevesAet al.Standardising joint assessment in rheumatoid arthritis.Clin Rheumatol1996;15 (6):579–582
29.
PopeJEBaronMBellamyNet al.Variability of skin scores and clinical measurements in scleroderma.J Rheumatol1995;22 (7):1271–1276
30.
CzirjákLNagyZAringerMRiemekastenGMatucci-CerinicMFurstDEEUSTAR.The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis2007;66 (7):966–969
31.
FoeldvariIWierkAHealthy children have a significantly increased skin score assessed with the modified Rodnan skin score.Rheumatology (Oxford)2006;45 (1):76–78
32.
SobanskiVDauchetLLefevreGet al.Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis.Arthritis Rheum2014;66 (2):407–417
